This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
We are interested in conducting research that will benefit the people of West Virginia. The application of what we learn from research is vital to the improvement of the health, quality of service, and patient care throughout West Virginia. Vandalia Health Charleston Area Medical Center is dedicated to providing the latest in new therapies and applications.
See below for a categorized listing of clinical trials currently underway at CAMC. You can also view all clinical trials.
Showing 91 - 95 of 95
(Closed at Site) Clinical and biological factors have been shown to have prognostic value in neuroblastoma. Current therapeutic studies for neuroblastoma patients are tailored according to patient risk. In the Children’s Oncology Group (COG), risk-group assignment is currently based on INSS stage, age, MYCN copy number, tumor cell ploidy, and International Neuroblastoma Pathology Classification (INPC) tumor histopathology. However, additional biologic factors have also been reported to be predictive of outcome. This study serves as the infrastructure for rapid and reliable acquisition of...
The primary objective of this study is to assess the effect of adjuvant treatment with olaparib on Invasive Disease-Free Survival (IDFS).
Note: This study is closed to accrual, meaning that the research team is no longer enrolling new subjects.
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
The investigational Vascular Covered Stent is a self-expanding, low profile, polytetrafluoroethylene encapsulated nitinol implant. It is deployed from a delivery system that provides controlled stent release.